| MATERIALS AND METHODS

| Device and procedure
The Nit-Occlud PDA device is a nitinol coil designed for PDA closure.
The device specification has been previously described in detail. 2 The
Nit-Occlud PDA device has a reverse-cone shape having proximal and distal coils that is made to fit into the ductal ampulla and anchor to the pulmonary side of the PDA ( Figure 1A ). There are six sizes available: 4 × 4 mm, 5 × 4 mm, 6 × 5 mm, 7 × 6 mm, 9 × 6 mm, 11 × 6 mm. Each device is named by diameter of distal coil diameter × proximal coil loop diameter. The smaller "Flexible" devices (4 × 4 mm, 5 × 4 mm, 6 × 5 mm) can be delivered through a 4-Fr delivery catheter, whereas the larger "Medium" devices (7 × 6 mm, 9 × 6 mm, 11 × 6 mm) require a 5-Fr delivery catheter. The size of device is selected according to the angiographic measurement of PDA on lateral aortography. The distal coil diameter should be no more than 2 mm larger than the aortic ampulla diameter and at least 3-4 mm larger than the pulmonary end and/or narrowest diameter of PDA. The length of device should not be longer than the ductal length.
The Nit-Occlud PDA device is usually deployed anterograde from the pulmonary side. Distal windings of the device are configured in the descending aorta (DAO) and pulled back to the ductal ampulla. Then, one of the "reverse cone" proximal windings are delivered at the pulmonary side. After confirming a satisfactory position of coil, the device is detached ( Figure 1B ). If embolized, the device can be retrieved by snaring any part of the coil and retracting it into a 6-Fr sheath.
| Study design
The Nit-Occlud PAS study was a prospective, nonrandomized multicenter trial conducted in 11 medical centers (Appendix 1) in the United States. The study evaluated the safety and effectiveness of the Nit-Occlud PDA device in the postapproval phase. The study's outcomes were defined to determine whether the Nit-Occlud PDA met or exceeded objective performance criteria (OPC) derived from historical results of device and surgical PDA closure. 3 Local institutional review board approval was obtained in each participating center for this study. Informed consent was obtained for each study subject.
Inclusion criteria were: age between 6 months and 21 years, weight ≥ 5 kg, and an angiographically confirmed PDA with a minimum diameter of <4 mm. Exclusion criteria included presence of associated cardiac anomalies requiring surgery, bleeding or clotting disorders, pulmonary hypertension (with pulmonary vascular resistance ≥5 Woods unit), contrast or nickel allergy, pregnancy and acute illnesses.
Patients were evaluated before and during cardiac catheterization, at hospital discharge, and 2 months, 12 months, and 24 months after device implant. Subjects with documented residual PDA shunt, any significant left pulmonary artery (LPA) or DAO obstruction and/or on ongoing device-related issue at 12 months were followed yearly postimplant for an additional 4 years (24 months, 48 months, and 60 months). At follow-up, subjects were evaluated on history, physical examination and transthoracic echocardiography. Subject data were maintained in an electronic study database. The consistency of reports with source patient data were confirmed by the periodic site audits.
| Outcome measures
The primary outcome of the PAS was effectiveness and safety at 12-month after device implant. In addition, these outcome measures were evaluated in the combined cohort of the pivotal, continued access and postapproval studies.
| Statistical analysis
Data were expressed as frequency (percentage) for binary outcomes.
Standard errors and exact 95% confidence intervals were calculated.
Statistical analysis was performed using the statistical softwares 
| RESULTS
A total of 184 subjects were enrolled from 11 sites in the PAS ( Figure 2 ). The median age of patients was 3.4 years (range 4 months Table 1 ).
The median minimum PDA diameter was 1.7 mm (range 0.6 mm-3.6 mm) with median PDA length of 8.0 mm (range 2.5 mm-21.9 mm).
PDA was classified angiographically as Krichenko 4 type A (conical)
83.7%, type B (short) 1.1%, type C (tubular) 2.2%, type D (complex)
3.3%, and type E (elongated) 9.8% (Table 1) .
Successful implantation was achieved in 180 of 184 patients (97.8%). There were four technical failures (2.2%), which were attributed to a larger ductal size in three and premature release of device in one. For the three cases in which the PDA was deemed too large for NitOcclud closure, the device was deployed but not released. After successful retrieval of the NitOcclud devices, non-study devices were used to close these four PDAs. Median total fluoroscopy time was 11.0 min. The median procedure duration was 52.5 min. Of the 184 subjects enrolled, 133 were discharged the same day as the implant procedure and the remaining 51 subjects were discharged the day after the procedure. 
| Efficacy and safety of postapproval study
Effectiveness endpoint was echocardiographic closure of PDA at 12-month postdevice implant (Table 3 ). This endpoint was also evaluated at hospital discharge, after 2 months, and after 12 months. At There were no deaths and no cases of hemolysis. There were no subjects having significant obstruction in the LPA or DAO on echocardiography at 12-month follow-up, which was defined as a mean gradient >10 mmHg. Thirteen patients had 16 serious adverse events (Table 4) . None of the serious adverse events were device-related, but three of the SAEs were probably or definitely procedure-related.
There were 6 (4.9%) device-related and 14 (11.5%) procedure-related non-SAEs that occurred within the 12-month follow-up period.
Device-related events included three device embolizations all of which occurred immediately following implantation (one embolized to the main pulmonary artery, one to the left femoral artery and a third to the abdominal aorta). In two cases, percutaneous retrieval was performed during the implantation procedure and another Nit-Occlud device was implanted successfully; the third subject was exited and a non-study device was implanted. Additional device-related AEs were device malposition (n = 1), and spontaneous detachment of coil from delivery cable without embolization (n = 3). Three procedure-related SAEs include the following: temporary loss of pulse requiring anticoagulation therapy (n = 2), left vocal cord paralysis (n = 1). Loss of pulse resolved at follow-up, whereas left vocal cord paralysis required ongoing speech therapy.
The other non-serious procedure-related AEs reported through 12 months were the following: access site hematoma (n = 8), device malposition (n = 2), inability to re-deploy device (n = 1), transient mitral regurgitation (n = 1), and allergic skin reaction to tape (n = 1).
Among 62 subjects completing 24-month follow-up, two subjects had late-onset procedure-related SAEs. These were both residual PDA shunts for which the operators chose to place additional non-study have been used off-label for PDA closure. As such, no FDA pivotal trial data are available for these devices.
In the pivotal trial for the ADO I, there were 393 patients. The 12-month closure rate was 98.6% and there were five (2.7%) serious adverse events including one death. 5 While direct comparisons of these devices are not perfect given subtle differences in the trials, clearly the closure rates are very similar. Both the ADO I and NitOcclud PDA have excellent overall device characteristics and outcomes for closure of small to moderate sized PDAs. 5, 6 As it is easily retrievable and repositionable using a low profile delivery catheter, the Nit-Occlud has very high technical success rate with minimal residual shunt at follow-up, and is unlikely to cause obstruction in the LPA and DAO.
| Study limitations
This study was a prospective observational study lacking a surgical or control group using an approved PDA device. Due to the absence of approved alternative coil-type PDA devices, the study was designed to compare the OPC benchmark designated by the FDA advisory panel. The PAS continues to follow-up the enrolled patients at 24 months postimplant and for 60 months for subjects with residual PDA shunt, any significant LPA or DAO obstruction, and/or an ongoing device-related issue at 12 months follow-up. Nevertheless, authors felt it reasonable to present the interim data of PAS.
| CONCLUSIONS
The Nit-Occlud PDA is a safe and effective device for closure of a small to moderate sized PDA in the PAS. At 12 months, echocardiographic closure was 95.9% with device-and procedure-related SAE of 0.6%. This efficacy and safety profile was well above or comparable to the OPC benchmark designated by the FDA advisory panel and contemporary practice data. 7 Most importantly, there were no serious adverse events including hemolysis, mortality or need of surgery in a large cohort of three clinical trials and all five device embolizations were percutaneously retrieved with a snare easily.
SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article. 
